1Pingitore A, Landi P, Taddei MC, et al. Triiodothyronine levels for risk stratification of patients with chronic heart fail- ure. Am J Med, 2005,118(2) :132-136.
2Spooner PH, MorkinE, Goldman S. Thyroid hormone and thyroid hor2mone analogues in the treatment of heart failure[J]. Coron Artery Dis,1999,10 (6) :395-399.
3Shanoudy H,Soliman A,Moe S,et al. Early manifestations of " sick euthyroid" syndrome in patients with compensated chronic heart failure[ J]. J Card Fail,2001,7(2) :146-152.
4Jakobs TG, Mentrup B, Schmutzler C, et al. Proniflammatory cytokines inhibit the expression and function of human type Ⅰ 5 deiodinase in HepG2 hepatocarcinoma cells[ J]. Eur J Endocfinol,2002, 146(4) :559-566.
5Yu J, Koenig RJ. Regulation of hepatocyte thyroxine 5 'deiodinase by T3 and nuclear receptor coactivators as a model of the sick euthyroid syndrome[ J ]. J Biol Chem,2000,275 (49) :38296-38301.
6Ishikawa T, Yanagisawa M, Kimura S, et al. Positive inotropie action of a novel vasoconstrictor peptide endothelin on guinea pig atria[ J]. Am J Physiology, 1988,255 (4 Pt 2 ) : H970-973.
7Shekhar YC, Anand IS, Sarmar R, et al. Effects of prolonged infusion of human Alpha calcitinin gene-related peptid on hemodynamics renal blood flow and hormone levels in C HF[ J]. Am J Cardiol, 1991,67 (8) :732-736.
8Sacca L. Growth hormone :a newcomer in cardiovascular medicine[ J].Cardiovascular Res, 1997,36(1) :3-9.
9Cuneo RC, Wilmshurst P, Lowy C, et al. Cardiac failure responding to growth hormone[J]. Lancet, 1989,1(8642) :838-839.
10Moruzzl P,Dofia E,Agostini PG, et al. Usefulness of L-thyroxin to improve cardiac and exercise performance in idiopathic dilated cardiomyopathy[ J]. Am J Cardiol, 1994,73 (5) : 374-378.
